RevealDx

Lung cancer is the #1 cancer killer because we lack actionable information to move patients into treatment faster. RevealDx has a Radiomic solution for early lung nodule characterization that can be deployed to millions chest CT scans an help catch cancer at the first scan.

RevealDx is a Seattle-based software company whose vision is to dramatically improve lung cancer outcomes. We do this by delivering the most advanced, radiomics and AI enabled, lung cancer decision support software to the mainstream market, driving the optimal clinical pathway for each patient.
CE Mark, UK MHRA-registered, Health Canada, TGA medical device license obtained. The product is not approved for clinical use in any other jurisdiction and the content herein is for informational purposes only. This product is covered by U.S. Patent No. 10,255,997